Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond.

Lemery, Steven; Pazdur, Richard

Lemery, Steven; Pazdur, Richard.

Lemery S; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. Steven.Lemery@fda.hhs.gov.
Pazdur R; Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.

Nat Rev Clin Oncol ; 19(4): 217-218, 2022 04.

Article in English | MEDLINE | ID: covidwho-1679815

Subject(s)

Antineoplastic Agents; Drug Approval; Antineoplastic Agents/therapeutic use; Humans; United States; United States Food and Drug Administration

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Approval / Antineoplastic Agents Limits: Humans Country/Region as subject: North America Language: English Journal: Nat Rev Clin Oncol Journal subject: Neoplasms Year: 2022 Document Type: Article Affiliation country: S41571-022-00605-5

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google